- Home
- BIAF vs POAI Comparison
BIAF vs POAI Comparison
Compare BIAF & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | POAI |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | 57 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIAF | POAI |
|---|---|---|
| Price | $1.50 | $5.58 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.9K | 42.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,776,739.00 | $1,664,407.00 |
| Revenue This Year | N/A | $486.27 |
| Revenue Next Year | $20.04 | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 320.71 |
| 52 Week Low | $1.25 | $3.88 |
| 52 Week High | $46.53 | $45.90 |
Technical Indicators
Market Signals| Indicator | BIAF | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 47.30 |
| Support Level | $1.60 | $3.88 |
| Resistance Level | $1.74 | $6.25 |
| Average True Range (ATR) | 0.12 | 0.76 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 26.76 | 79.01 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.